Trial Profile

A pivotal phase III assessing Spherotide in patients with endometriosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triptorelin (Primary)
Indications Endometriosis
Focus Registrational; Therapeutic Use
Sponsors Xbrane

Most Recent Events

29 Jul 2019 New trial record
04 Jun 2019 According to a Xbrane media release, this trial has been planned to support market authorization for endometriosis, myoma and breast cancer indications in both Europe and China.
04 Jun 2019 According to a Xbrane media release, based on the interim data of this study, further clinical trials in prostate cancer patients for both 1-month and 3-month formulations will be conducted.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com